1. This application is for diamond dinitrotoluene compounds and their salts, solutions or stereoisomers which are acceptable for medicine. It also provides synthesis and use in methods to treat cancer, diabetes or polio. 1. Claim 1: a compound with formula structure (1): each R 1 is an independent halogen, - CN, - no832222；-Or83088,-8308； 83088；1. Lease land No. c833218331 and 832626；haloalkyl C₁₋₆,haloalkoxy C₁₋₆,e. Alternative substitution, - C (o) R3,-OC (O) R-CO₂R⁴,-N (R) C (O) R-C (O) NR R-N (R) C (O) NR R-S (O) R-N (R) S (O) RO-S (o) 8322； 8309； r8310；each R² is independently C₁₋₆ alkyl,C₁₋₆ alkoxy,haloalkyl C₁₋₆,haloalkoxy C₁₋₆,optionally substituted C₁₋₆ heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl； each R³ is independently C₁₋₆-alkyl；each R⁴ is independently H or C₁₋₆ alkyl；each R⁵ and each R⁶ are independently H or C₁₋₆ alkyl；or R⁵ and R⁶ together with the nitrogen atom to which they are attached form an optionally substituted C₁₋₆ heterocycloalkyl； p is 0, 1, 2, 3, 4 or 5； and q is 0, 1, 2, 3 or 4； or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. Claim 18: A compound of formula (2) where: each R¹ is independently halogen, -CN, -NO₂,-Or83088,-8308； 83088；1. Lease land No. c833218331 and 832626；haloalkyl C₁₋₆,haloalkoxy C₁₋₆,e. Alternative substitution, - C (o) R3,-OC (O) R-CO₂R⁴,-N (R) C (O) R-C (O) NR R-N (R) C (O) NR R-S (O) R-N (R) S (O) RO-S (o) 8322； 8309； r8310；each R² is independently C₁₋₆ alkyl,C₁₋₆ alkoxy,haloalkyl C₁₋₆,haloalkoxy C₁₋₆,optionally substituted C₁₋₆ heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl； each R³ is independently C₁₋₆-alkyl；each R⁴ is independently H or C₁₋₆ alkyl；each R⁵ and each R⁶ are independently H or C₁₋₆ alkyl；or R⁵ and R⁶ together with the nitrogen atom to which they are attached form an optionally substituted C₁₋₆ heterocycloalkyl； p is 1, 2, 3, 4 or 5； and q is 0, 1, 2, 3 or 4； or a pharmaceutically acceptable salt, s
